Price History

Hover for the daily close. The dotted line marks the period open.

Compare MSLE with… →

MSLE Key Statistics

As of Sep 4, 2026

Trading

Open: $9.13
Previous Close: $9.08
Day's Range: 8.97–9.25
52-Week Range: 5.30–13.40
Volume: 24.69K
Beta: 1.14

Valuation

Market Cap: $190.31M
P/E Ratio: unprofitable
EPS (ttm): −1.91

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$24.87M
Profit margin: 0.00%
Shares Outstanding: 21.22M
1-Year Return: +62.15%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 52.98K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MSLE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−78.77%+88.95%+52.55%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+52.55%
2025	−16.95%
2024	+81.54%
2023	+88.95%
2022	−78.77%
2021	−17.35%
2020	−7.55%
2019	+65.63%
2018	+6.67%
2017	−6.25%
2016 (partial year)	−43.86%

As of September 4, 2026.

MSLE Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$24.87M	—
2024	$0.00	−$20.63M	—
2023	$0.00	−$11.98M	—
2022	$0.00	−$8.34M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$26.46M	−$24.87M	—
2024	$0.00	—	−$20.40M	−$20.63M	—
2023	$0.00	—	−$11.66M	−$11.98M	—
2022	$0.00	—	−$6.21M	−$8.34M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MSLE Valuation vs Biotechnology Median

Median of 654 stocks

Metric	MSLE	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 654 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Satellos Bioscience Inc. (MSLE) is capitalised at $190.31M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 18.

The 52-week range on file runs from $5.30 to $13.40. The most recent close on file for MSLE is $8.97, dated September 4, 2026. That is −$0.11 (−1.21%) against the previous close. The latest close sits 69.12% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $24.87M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.91.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.14. Annualized volatility over the trailing 10 years is 1,868.49%. Over the trailing twelve months the price has returned +62.15%. Across 10 years the annualized return works out at −3.43%.

Growth & Income

The record shows no dividend for MSLE.

So far in 2026 the price is +52.55%. The strongest complete calendar year on file is 2023 at +88.95%; the weakest is 2022 at −78.77%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Satellos Bioscience Inc. (MSLE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Satellos Bioscience Inc.	MSLE	$190.31M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	31.8
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	39.4

The Biotechnology industry average P/E ratio is 12.9x. Satellos Bioscience Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Satellos Bioscience Inc.

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Visit website →

Satellos Bioscience Inc. (MSLE) Stock Analysis